Wang Feng, Eikeland Eline, Reidunsdatter Randi J, Hagen Lars, Engstrøm Monica J, Geisler Jürgen, Haanpää Mikko, Hämäläinen Esa, Giskeødegård Guro F, Bathen Tone F
Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Breast and Endocrine of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Front Oncol. 2024 May 28;14:1383104. doi: 10.3389/fonc.2024.1383104. eCollection 2024.
Systemic and local steroid hormone levels may function as novel prognostic and predictive biomarkers in breast cancer patients. We aimed at developing a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous measurement of multiple, biologically pivotal steroid hormones in human serum and breast cancer tissue.
The quantitative method consisted of liquid-liquid extraction, Sephadex LH-20 chromatography for tissue extracts, and analysis of steroid hormones by liquid-chromatography-tandem mass spectrometry. We analyzed serum and tissue steroid hormone levels in 16 and 40 breast cancer patients, respectively, and assessed their correlations with clinical parameters.
The method included quantification of nine steroid hormones in serum [including cortisol, cortisone, corticosterone, estrone (E1), 17β-estradiol (E2), 17α-hydroxyprogesterone, androstenedione (A4), testosterone and progesterone) and six (including cortisone, corticosterone, E1, E2, A4, and testosterone) in cancer tissue. The lower limits of quantification were between 0.003-10 ng/ml for serum (250 µl) and 0.038-125 pg/mg for tissue (20 mg), respectively. Accuracy was between 98%-126%, intra-assay coefficient of variations (CV) was below 15%, and inter-assay CV were below 11%. The analytical recoveries for tissue were between 76%-110%. Tissue levels of E1 were positively correlated with tissue E2 levels (p<0.001), and with serum levels of E1, E2 and A4 (p<0.01). Tissue E2 levels were positively associated with serum E1 levels (p=0.02), but not with serum E2 levels (p=0.12). The levels of tissue E2 and ratios of E1 to A4 levels (an index for aromatase activity) were significantly higher in patients with larger tumors (p=0.03 and p=0.02, respectively).
The method was convenient and suitable for a specific and accurate profiling of clinically important steroid hormones in serum. However, the sensitivity of the profile method in steroid analysis in tissue samples is limited, but it can be used for the analysis of steroids in breast cancer tissues if the size of the sample or its steroid content is sufficient.
全身和局部类固醇激素水平可能作为乳腺癌患者新的预后和预测生物标志物。我们旨在开发一种新型液相色谱 - 串联质谱(LC-MS/MS)方法,用于同时测定人血清和乳腺癌组织中多种具有生物学关键作用的类固醇激素。
定量方法包括液 - 液萃取、用于组织提取物的葡聚糖LH - 20色谱法以及通过液相色谱 - 串联质谱法分析类固醇激素。我们分别分析了16例和40例乳腺癌患者的血清和组织类固醇激素水平,并评估了它们与临床参数的相关性。
该方法包括定量血清中的九种类固醇激素[包括皮质醇、可的松、皮质酮、雌酮(E1)、17β - 雌二醇(E2)、17α - 羟孕酮、雄烯二酮(A4)、睾酮和孕酮]以及癌组织中的六种(包括可的松、皮质酮、E1、E2、A4和睾酮)。血清(250μl)的定量下限分别为0.003 - 10 ng/ml,组织(20 mg)的定量下限为0.038 - 125 pg/mg。准确度在98% - 126%之间,批内变异系数(CV)低于15%,批间CV低于11%。组织的分析回收率在76% - 110%之间。组织E1水平与组织E2水平呈正相关(p < 0.001),与血清E1、E2和A4水平呈正相关(p < 0.01)。组织E2水平与血清E1水平呈正相关(p = 0.02),但与血清E2水平无相关性(p = 0.12)。肿瘤较大的患者组织E2水平和E1与A4水平的比值(芳香化酶活性指标)显著更高(分别为p = 0.03和p = 0.02)。
该方法简便,适用于血清中临床重要类固醇激素的特异性和准确分析。然而,该分析方法对组织样本中类固醇分析的灵敏度有限,但如果样本大小或其类固醇含量足够,可用于乳腺癌组织中的类固醇分析。